|

SHR-A1921 Clinical Trials

5 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 2: 4Phase 3: 1

Top Sponsors

Fudan University3
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
Beijing GoBroad Hospital1

Indications

Cancer5
Breast Cancer4
HER2-negative Breast Cancer3
Advanced Breast Cancer3
Hormone Receptor Positive Tumor2

Other5 trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Phase 3

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.